Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 4,120 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus (HIV) Infection Clear all
Completed Not applicable Interventional Results available

WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)

NCT04373551
View directory record Official record
Conditions
HIV-infection/AIDS
Interventions
Cultural adaptation of a patient-provider communication tool
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 9:03 PM EDT
Completed No phase listed Observational

Long-term Follow-up of HIV Infected Patients Identified During Early Infection

NCT00086372
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 15, 2026, 9:03 PM EDT
Completed No phase listed Observational

Age-17 Follow-up of Home Visiting Intervention

NCT00708695
View directory record Official record
Conditions
Antisocial Behavior, Psychopathology, Substance Use, HIV Infections
Interventions
Nurse Home Visiting
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
17 Years to 65 Years
Enrollment
1,880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stepped Care for Youth Living With HIV

NCT03109431
View directory record Official record
Conditions
HIV, Mental Health, Illicit Substance Use, Sexually Transmitted Infections (STI)
Interventions
Level 1, Level 2, Level 3
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 24 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Los Angeles, California • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

NCT00000853
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
3
States / cities
Birmingham, Alabama • Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Feasibility of Using a Structured Daily Diary

NCT01953653
View directory record Official record
Conditions
HIV Infection
Interventions
Structured daily diary
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years · Male only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Aurora, Colorado • Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Youth to Text or Telehealth for Engagement in HIV Care

NCT03681145
View directory record Official record
Conditions
HIV/AIDS, Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Depression, Substance Use
Interventions
Counselor delivered telehealth intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 29 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 15, 2026, 9:03 PM EDT
Not listed Phase 3 Interventional

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

NCT00005002
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate
Drug · Biological
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study

NCT00002037
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Trifluridine
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 3 Interventional

A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children

NCT00000637
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 17 Years
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
76
States / cities
Birmingham, Alabama • Downey, California • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Results available

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

NCT00757783
View directory record Official record
Conditions
HIV
Interventions
ritonavir, darunavir, emtricitabine [FTC]/tenofovir [TDF], atazanavir
Drug
Lead sponsor
Tibotec, Inc
Industry
Eligibility
18 Years to 99 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
15
States / cities
Los Angeles, California • Glastonbury, Connecticut • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 1Phase 2 Interventional

Marijuana for HIV-Related Peripheral Neuropathy

NCT00046722
View directory record Official record
Conditions
Peripheral Nervous System Diseases, HIV Infections
Interventions
Smoked Marijuana
Drug
Lead sponsor
Center for Medicinal Cannabis Research
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2007 · Synced Oct 15, 2026, 9:03 PM EDT
Completed No phase listed Observational

A Study of Patients With AIDS Syndrome

NCT00001120
View directory record Official record
Conditions
Sarcoma, Kaposi, Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, AIDS-Related
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Menlo Park, California • San Francisco, California • San Rafael, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2008 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals

NCT01286259
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Disulfiram
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

NCT00002127
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Thalidomide
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Greenbrae, California • Redwood City, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PlusCare: Mobile Platform to Increase Linkage to Care in Adolescents Living With HIV/AIDS

NCT03758066
View directory record Official record
Conditions
HIV/AIDS
Interventions
PlusCare
Device
Lead sponsor
Dimagi Inc.
Industry
Eligibility
13 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Within My Reach (WMR) Adaptation

NCT06056661
View directory record Official record
Conditions
Hiv, Violence
Interventions
WMR
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

NCT01504841
View directory record Official record
Conditions
HIV Infections
Interventions
Etravirine (ETR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient

NCT00000661
View directory record Official record
Conditions
HIV Infections
Interventions
Oxazepam, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Oct 15, 2026, 9:03 PM EDT
Withdrawn Phase 1 Interventional

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

NCT02343666
View directory record Official record
Conditions
Human Immunodeficiency Virus 1 Positive, Stage I Adult Hodgkin Lymphoma, Stage I Adult Non-Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult Non-Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Non-Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Non-Hodgkin Lymphoma
Interventions
C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs, Carmustine, Filgrastim, Laboratory Biomarker Analysis, O6-Benzylguanine, Plerixafor
Biological · Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 66 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 15, 2026, 9:03 PM EDT
Active, not recruiting Not applicable Interventional

Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South Africa: Part 2

NCT06182241
View directory record Official record
Conditions
Cervical Cancer, Hiv
Interventions
Retention in cervical cancer care intervention
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3

NCT00000756
View directory record Official record
Conditions
HIV Infections
Interventions
Lymphocytes, Activated
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 15, 2026, 9:03 PM EDT
Completed No phase listed Observational

Prospective Observational Study on the Incidence of Opportunistic Fungal Infections

NCT05707156
View directory record Official record
Conditions
Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis, Candidiasis, Aspergillosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
12,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 15, 2026, 9:03 PM EDT
Completed Not applicable Interventional

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3

NCT00002161
View directory record Official record
Conditions
HIV Infections
Interventions
Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Birmingham, Alabama • Berkeley, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 9:03 PM EDT